{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:05:29Z","timestamp":1789650329702,"version":"4.0.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-25-00204"],"award-info":[{"award-number":["24-25-00204"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03118-0","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:09:15Z","timestamp":1763132955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiogenomics: transforming lung cancer care through non-invasive imaging and genomic integration"],"prefix":"10.1007","volume":"42","author":[{"given":"Faridoddin","family":"Shariaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalii","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"2","key":"3118_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.62347\/DDRR4923","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yang G, Gao X, Li L, Zhu H, Yi H. Subregion-specific 18F-FDG PET-CT radiomics for the pre-treatment prediction of EGFR mutation status in solid lung adenocarcinoma. Am J Nucl Med Mol Imaging. 2024;14(2):134.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"3118_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10:71.","journal-title":"Nat Rev Dis Primers"},{"key":"3118_CR3","doi-asserted-by":"publisher","first-page":"1173355","DOI":"10.3389\/fonc.2023.1173355","volume":"13","author":"Y Zuo","year":"2023","unstructured":"Zuo Y, Liu Q, Li N, Li P, Zhang J, Song S. Optimal 18F-FDG PET\/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study. Front Oncol. 2023;13:1173355.","journal-title":"Front Oncol"},{"issue":"10","key":"3118_CR4","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563\u201379.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3118_CR5","unstructured":"Board, P. A. T. E. Non-small cell lung cancer treatment (PDQ\u00ae): health professional version. PDQ Cancer Information Summaries [Internet]. 2002."},{"key":"3118_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00408-023-00661-3","volume":"201","author":"AEC Daylan","year":"2023","unstructured":"Daylan AEC, Miao E, Tang K, et al. Lung cancer in never smokers: delving into epidemiology, genomic and immune landscape, prognosis, treatment, and screening. Lung. 2023;201:521\u20139.","journal-title":"Lung"},{"issue":"4","key":"3118_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.37349\/etat.2023.00158","volume":"4","author":"A Mahajan","year":"2023","unstructured":"Mahajan A, Gurukrishna B, Wadhwa S, et al. Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer. Explor Target Anti-tumor Ther. 2023;4(4):657.","journal-title":"Explor Target Anti-tumor Ther"},{"key":"3118_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107831","volume":"192","author":"Li Peng","year":"2024","unstructured":"Peng Li, Lidan H, Cuicui Z, et al. DNA double-strand break repair capacity and its pathway gene variants predict the risk and prognosis of lung cancer. Lung Cancer. 2024;192:107831.","journal-title":"Lung Cancer"},{"issue":"11","key":"3118_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.prp.2017.09.028","volume":"213","author":"DH Lee","year":"2017","unstructured":"Lee DH, Heo Y-R, Park W-J, Lee J-H. A TERT-CLPTM1 locus polymorphism (rs401681) is associated with EGFR mutation in non-small cell lung cancer. Pathol Res Practice. 2017;213(11):1340\u20133.","journal-title":"Pathol Res Practice"},{"key":"3118_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41435-018-0033-0","volume":"20","author":"J Xu","year":"2019","unstructured":"Xu J, Shang Y, Cai F, et al. Correlation between lung cancer and the HHIP polymorphisms of chronic obstructive pulmonary disease (COPD) in the Chinese Han population. Genes Immun. 2019;20:273\u201380.","journal-title":"Genes Immun"},{"issue":"5","key":"3118_CR11","first-page":"2264","volume":"11","author":"H Du","year":"2021","unstructured":"Du H, Liu L, Liu H, et al. Genetic variants of DOCK2, EPHB1 and VAV2 in the natural killer cell-related pathway are associated with non-small cell lung cancer survival. Am J Cancer Res. 2021;11(5):2264\u201377.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"3118_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.lungcan.2012.07.009","volume":"78","author":"M Tiseo","year":"2012","unstructured":"Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 2012;78(1):92\u20139.","journal-title":"Lung Cancer"},{"issue":"10","key":"3118_CR13","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.21037\/jtd-24-244","volume":"16","author":"F Lococo","year":"2024","unstructured":"Lococo F, Ghaly G, Flamini S, et al. Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives. J Thorac Dis. 2024;16(10):7096.","journal-title":"J Thorac Dis"},{"issue":"S1","key":"3118_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35783","volume":"131","author":"K Shaverdashvili","year":"2025","unstructured":"Shaverdashvili K, Burns TF. Advances in the treatment of KRASG12C mutant non\u2013small cell lung cancer. Cancer. 2025;131(S1):e35783.","journal-title":"Cancer"},{"key":"3118_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15523","author":"H Hatano","year":"2024","unstructured":"Hatano H, Yoshida T, Higashiyama R, et al. EGFR, TP53, and CUL3 triple mutation in non-small cell lung cancer and its potentially poor prognosis: a case report and database analysis. Thorac Cancer. 2024. https:\/\/doi.org\/10.1111\/1759-7714.15523.","journal-title":"Thorac Cancer"},{"key":"3118_CR16","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/mc.23750","volume":"63","author":"X Liang","year":"2024","unstructured":"Liang X, Jiali Xu, Jiang Y, et al. Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer. Mol Carcinog. 2024;63:1643\u201353.","journal-title":"Mol Carcinog"},{"key":"3118_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.011","volume":"106","author":"PA VanderLaan","year":"2017","unstructured":"VanderLaan PA, Rangachari D, Mockus SM, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer. 2017;106:17\u201321.","journal-title":"Lung Cancer"},{"issue":"2","key":"3118_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pathol.2023.11.006","volume":"56","author":"I Odintsov","year":"2024","unstructured":"Odintsov I, et al. Prognostic and predictive biomarkers in non-small cell lung carcinoma. Pathology. 2024;56(2):192\u2013204.","journal-title":"Pathology"},{"key":"3118_CR19","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/diagnostics10110902","volume":"10","author":"E Marin","year":"2020","unstructured":"Marin E, Reyes R, Arcocha A, et al. Prospective evaluation of single nucleotide variants by two different technologies in paraffin samples of advanced non-small cell lung cancer patients. Diagnostics. 2020;10:902.","journal-title":"Diagnostics"},{"key":"3118_CR20","volume":"86","author":"J Ra\u00ebth","year":"2024","unstructured":"Ra\u00ebth J, Malbert C, Pinsolle J, et al. Different pathways to lung cancer diagnosis in a real-life setting. Respir Med Res. 2024;86:101108.","journal-title":"Respir Med Res"},{"issue":"5","key":"3118_CR21","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3892\/ol.2017.5921","volume":"13","author":"W Lian","year":"2017","unstructured":"Lian W, Ouyang Y. CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer. Oncol Lett. 2017;13(5):3415\u201322.","journal-title":"Oncol Lett"},{"key":"3118_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00330-015-3814-0","volume":"26","author":"S Rizzo","year":"2016","unstructured":"Rizzo S, Petrella F, Buscarino V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol. 2016;26:32\u201342.","journal-title":"Eur Radiol"},{"issue":"2","key":"3118_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14616","volume":"26","author":"D Jin","year":"2025","unstructured":"Jin D, Ni X, Tan Y, Yin H, Fan G. Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer. J Appl Clin Med Phys. 2025;26(2):e14616.","journal-title":"J Appl Clin Med Phys"},{"issue":"1","key":"3118_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13823-8","volume":"25","author":"P Cao","year":"2025","unstructured":"Cao P, Jia X, Wang X, Fan L, Chen Z, Zhao Y, et al. Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients. BMC Cancer. 2025;25(1):443.","journal-title":"BMC Cancer"},{"key":"3118_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111111","author":"K Xu","year":"2021","unstructured":"Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021. https:\/\/doi.org\/10.1016\/j.biopha.2020.111111.","journal-title":"Biomed Pharmacother"},{"key":"3118_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12967-022-03599-x","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang S, Xia H, et al. The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer. J Transl Med. 2022;20:404.","journal-title":"J Transl Med"},{"key":"3118_CR27","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1007\/s00259-024-06794-8","volume":"51","author":"M Masse","year":"2024","unstructured":"Masse M, Chardin D, Tricarico P, et al. [18F]FDG-PET\/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. Eur J Nucl Med Mol Imaging. 2024;51:3696\u2013708.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1122","key":"3118_CR28","doi-asserted-by":"publisher","first-page":"20201272","DOI":"10.1259\/bjr.20201272","volume":"94","author":"M Abdurixiti","year":"2021","unstructured":"Abdurixiti M, Nijiati M, Shen R, Ya Q, Abuduxiku N, Nijiati M. Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET\/CT images: a systematic review. Br J Radiol. 2021;94(1122):20201272.","journal-title":"Br J Radiol"},{"key":"3118_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563\u201377.","journal-title":"Radiology"},{"key":"3118_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105230","volume":"142","author":"I Shiri","year":"2022","unstructured":"Shiri I, Amini M, Nazari M, Hajianfar G, et al. Impact of feature harmonization on radiogenomics analysis: prediction of EGFR and KRAS mutations from non-small cell lung cancer PET\/CT images. Comput Biol Med. 2022;142:105230.","journal-title":"Comput Biol Med"},{"issue":"21","key":"3118_CR31","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJ Van Griethuysen","year":"2017","unstructured":"Van Griethuysen JJ, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Can Res. 2017;77(21):e104\u20137.","journal-title":"Can Res"},{"key":"3118_CR32","volume":"5","author":"CT Take","year":"2024","unstructured":"Take CT. get PET free: AI-powered breakthrough in lung cancer diagnosis and prognosis. Cell Rep Med. 2024;5:101463.","journal-title":"Cell Rep Med"},{"issue":"6","key":"3118_CR33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10278-013-9622-7","volume":"26","author":"K Clark","year":"2013","unstructured":"Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The cancer imaging archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013;26(6):1045\u201357.","journal-title":"J Digit Imaging"},{"issue":"2","key":"3118_CR34","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1118\/1.3528204","volume":"38","author":"SG Armato III","year":"2011","unstructured":"Armato SG III, McLennan G, Bidaut L, McNitt-Gray MF, Meyer CR, Reeves AP, et al. The lung image database consortium (LIDC) and image database resource initiative (IDRI): a completed reference database of lung nodules on CT scans. Med Phys. 2011;38(2):915\u201331.","journal-title":"Med Phys"},{"issue":"1","key":"3118_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/s41597-024-04085-3","volume":"11","author":"B Zhao","year":"2024","unstructured":"Zhao B, Dercle L, Yang H, Riely GJ, Kris MG, Schwartz LH. Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters. Sci Data. 2024;11(1):1259.","journal-title":"Sci Data"},{"issue":"1","key":"3118_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40644-025-00856-2","volume":"25","author":"W Chen","year":"2025","unstructured":"Chen W, Lin G, Feng Y, et al. Intratumoral and peritumoral CT radiomics in predicting anaplastic lymphoma kinase mutations and survival in patients with lung adenocarcinoma: a multicenter study. Cancer Imaging. 2025;25(1):35.","journal-title":"Cancer Imaging"},{"issue":"2","key":"3118_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJ, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328\u201338.","journal-title":"Radiology"},{"key":"3118_CR38","doi-asserted-by":"publisher","first-page":"603882","DOI":"10.3389\/fonc.2021.603882","volume":"11","author":"C Chang","year":"2021","unstructured":"Chang C, Sun X, Wang, et al. A machine learning model based on PET\/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. Front Oncol. 2021;11:603882.","journal-title":"Front Oncol"},{"issue":"1","key":"3118_CR39","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","volume":"5","author":"HJ Aerts","year":"2014","unstructured":"Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5(1):4006.","journal-title":"Nat Commun"},{"issue":"4","key":"3118_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175622","volume":"12","author":"K Takamochi","year":"2017","unstructured":"Takamochi K, Mogushi K, Kawaji H, Imashimizu K, Fukui M, Oh S, et al. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS ONE. 2017;12(4):e0175622.","journal-title":"PLoS ONE"},{"key":"3118_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107449","volume":"188","author":"YH Zhang","year":"2024","unstructured":"Zhang YH, Liu XS, Gao Y, et al. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters. Lung Cancer. 2024;188:107449.","journal-title":"Lung Cancer"},{"key":"3118_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107896","volume":"194","author":"D Fujimoto","year":"2024","unstructured":"Fujimoto D, Hayashi H, Murotani K, Toi Y, Yokoyama T, Kato T, et al. Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: a multicenter cohort study (WJOG15121L: REAL-WIND). Lung Cancer. 2024;194:107896.","journal-title":"Lung Cancer"},{"key":"3118_CR43","doi-asserted-by":"publisher","first-page":"108248","DOI":"10.1016\/j.compbiolchem.2024.108248","volume":"113","author":"U Arif","year":"2024","unstructured":"Arif U, Zhang C, Hussain S, Abbasi AR. An efficient interpretable stacking ensemble model for lung cancer prognosis. Comput Biol Chem. 2024;113:108248. https:\/\/doi.org\/10.1016\/j.compbiolchem.2024.108248.","journal-title":"Comput Biol Chem"},{"key":"3118_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, Engler S, Haberecker M, R\u00fcschoff JH, Moch H, de Souza N, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42:369\u2013412.","journal-title":"Cancer Cell"},{"key":"3118_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-11341-y","author":"N Barry","year":"2025","unstructured":"Barry N, Kendrick J, Molin K, Li S, et al. Evaluating the impact of the Radiomics Quality Score: a systematic review and meta-analysis. Eur Radiol. 2025. https:\/\/doi.org\/10.1007\/s00330-024-11341-y.","journal-title":"Eur Radiol"},{"issue":"3","key":"3118_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/bjs.9736","volume":"102","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148\u201358.","journal-title":"Br J Surg"},{"issue":"1","key":"3118_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12880-024-01221-8","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Wang J, Huang X, Zhou Y, Qi J, Sun X, et al. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer. BMC Med Imaging. 2024;24(1):45.","journal-title":"BMC Med Imaging"},{"issue":"2","key":"3118_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000550","volume":"8","author":"B He","year":"2020","unstructured":"He B, Dong D, She Y, Zhou C, Fang M, Zhu Y, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer. 2020;8(2):e000550.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3118_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41698-023-00473-x","volume":"7","author":"LC Roisman","year":"2023","unstructured":"Roisman LC, Kian W, Anoze A, Fuchs V, Spector M, Steiner R, et al. Radiological artificial intelligence-predicting personalized immunotherapy outcomes in lung cancer. NPJ precision oncology. 2023;7(1):125.","journal-title":"NPJ precision oncology"},{"issue":"9","key":"3118_CR50","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.21037\/tlcr-24-416","volume":"13","author":"Z Chen","year":"2024","unstructured":"Chen Z, Chen X, Ju L, Li Y, Li W, Pang H. Establishing a predictive model for tumor mutation burden status based on 18F-FDG PET\/CT and clinical features of non-small cell lung cancer patients. Transl Lung Cancer Res. 2024;13(9):2269.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"3118_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1148\/radiol.211582","volume":"303","author":"R Perez-Johnston","year":"2022","unstructured":"Perez-Johnston R, Araujo-Filho JA, Connolly JG, Caso R, Whiting K, Tan KS, et al. CT-based radiogenomic analysis of clinical stage I lung adenocarcinoma with histopathologic features and oncologic outcomes. Radiology. 2022;303(3):664\u201372.","journal-title":"Radiology"},{"issue":"2","key":"3118_CR52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00330-022-09055-0","volume":"33","author":"J Li","year":"2023","unstructured":"Li J, Qiu Z, Zhang C, Chen S, Wang M, Meng Q, et al. Ithscore: comprehensive quantification of intra-tumor heterogeneity in NSCLC by multi-scale radiomic features. Eur Radiol. 2023;33(2):893\u2013903.","journal-title":"Eur Radiol"},{"key":"3118_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414954","volume":"15","author":"G Ye","year":"2024","unstructured":"Ye G, Wu G, Zhang C, Wang M, Liu H, Song E, et al. CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer. Front Immunol. 2024;15:1414954.","journal-title":"Front Immunol"},{"issue":"1","key":"3118_CR54","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1038\/s41598-020-60868-9","volume":"10","author":"BW Park","year":"2020","unstructured":"Park BW, Kim JK, Heo C, Park KJ. Reliability of CT radiomic features reflecting tumor heterogeneity according to image quality and image processing parameters. Sci Rep. 2020;10(1):3852.","journal-title":"Sci Rep"},{"issue":"6","key":"3118_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002118","volume":"9","author":"W Mu","year":"2021","unstructured":"Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET\/CT images. J Immunother Cancer. 2021;9(6):e002118.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3118_CR56","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"19","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180\u201391.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3118_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1148\/radiol.2017161845","volume":"286","author":"Mu Zhou","year":"2018","unstructured":"Zhou Mu, Leung A, Echegaray S, et al. Non-small cell lung cancer radiogenomics map identifies relationships between molecular and imaging phenotypes with prognostic implications. Radiology. 2018;286(1):307\u201315.","journal-title":"Radiology"},{"key":"3118_CR58","doi-asserted-by":"publisher","DOI":"10.21037\/actr-23-12","author":"M Del Re","year":"2024","unstructured":"Del Re M, Russo A, Rolfo C. Changing the way we treat KRAS G12C non-small cell lung cancers. AME Clinical Trials Review. 2024. https:\/\/doi.org\/10.21037\/actr-23-12.","journal-title":"AME Clinical Trials Review"},{"key":"3118_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03685-0","author":"S Li","year":"2024","unstructured":"Li S, Hu Y, Tian C, et al. Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) by 18F-FDG PET\/CT radiomics. Clin Transl Oncol. 2024. https:\/\/doi.org\/10.1007\/s12094-024-03685-0.","journal-title":"Clin Transl Oncol"},{"key":"3118_CR60","doi-asserted-by":"publisher","first-page":"1281572","DOI":"10.3389\/fonc.2024.1281572","volume":"14","author":"N Ma","year":"2024","unstructured":"Ma N, Yang W, Wang Q, et al. Predictive value of 18F-FDG PET\/CT radiomics for EGFR mutation status in non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2024;14:1281572.","journal-title":"Front Oncol"},{"issue":"7","key":"3118_CR61","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1002\/mp.16947","volume":"51","author":"Y Zuo","year":"2024","unstructured":"Zuo Y, Liu L, Chang C, et al. Value of multi-center 18F-FDG PET\/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma. Med Phys. 2024;51(7):4872\u201387.","journal-title":"Med Phys"},{"key":"3118_CR62","doi-asserted-by":"publisher","unstructured":"Fuster-Matanzo A, Pic\u00f3-Peris A, Bellv\u00eds-Bataller F, et al. Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods. Eur Radiol. 2025. https:\/\/doi.org\/10.1007\/s00330-025-11962-x.","DOI":"10.1007\/s00330-025-11962-x"},{"key":"3118_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","volume":"170","author":"M Johnson","year":"2022","unstructured":"Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer. 2022;170:41\u201351.","journal-title":"Lung Cancer"},{"issue":"2","key":"3118_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"key":"3118_CR65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: flaura China, a randomized study. Target Oncol. 2021;16:165\u201376.","journal-title":"Target Oncol"},{"issue":"7","key":"3118_CR66","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"9","key":"3118_CR67","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","volume":"35","author":"E Felip","year":"2024","unstructured":"Felip E, Cho BC, Guti\u00e9rrez V, Alip A, Besse B, Lu S, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805\u201316.","journal-title":"Ann Oncol"},{"issue":"1","key":"3118_CR68","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41598-023-50984-7","volume":"14","author":"J Lu","year":"2024","unstructured":"Lu J, Ji X, Liu X, Jiang Y, Li G, Fang P, et al. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC. Sci Rep. 2024;14(1):446.","journal-title":"Sci Rep"},{"issue":"1","key":"3118_CR69","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41747-023-00380-7","volume":"7","author":"Y Li","year":"2023","unstructured":"Li Y, Lv X, Wang Y, Xu Z, Lv Y, Hou D. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy. Eur Radiol Exp. 2023;7(1):64.","journal-title":"Eur Radiol Exp"},{"key":"3118_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00369","volume":"10","author":"L Song","year":"2020","unstructured":"Song L, Zhu Z, Mao L, Li X, Han W, Du H, et al. Clinical, conventional CT and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients. Front Oncol. 2020;10:369.","journal-title":"Front Oncol"},{"issue":"1","key":"3118_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/life15010083","volume":"15","author":"M Sch\u00f6neck","year":"2025","unstructured":"Sch\u00f6neck M, Rehbach N, Lotter-Becker L, et al. Machine learning-based radiomics analysis for identifying KRAS mutations in non-small-cell lung cancer from CT images: challenges, insights and implications. Life. 2025;15(1):83.","journal-title":"Life"},{"issue":"2","key":"3118_CR72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.lungcan.2015.09.018","volume":"90","author":"AJ Plodkowski","year":"2015","unstructured":"Plodkowski AJ, Drilon A, Halpenny DF, O\u2019Driscoll D, Blair D, Litvak AM, et al. From genotype to phenotype: are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements? Lung Cancer. 2015;90(2):321\u20135.","journal-title":"Lung Cancer"},{"issue":"5","key":"3118_CR73","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/cancers17050730","volume":"17","author":"M Piazzolla","year":"2025","unstructured":"Piazzolla M, Parente P, Centra F, et al. Distribution of EGFR and KRAS mutations in patients with surgically resected non-small cell lung cancer from southern Italy: real-life data from a single institution and literature review. Cancers (Basel). 2025;17(5):730.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3118_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tlcr-23-606","volume":"13","author":"A Zeng","year":"2024","unstructured":"Zeng A, Xiong Y, Zhang J, et al. Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center. Transl Lung Cancer Res. 2024;13(1):16.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3118_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.21037\/tlcr.2017.01.02","volume":"6","author":"JW Gao","year":"2017","unstructured":"Gao JW, Rizzo S, Ma LH, et al. Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology. Transl Lung Cancer Res. 2017;6(1):68\u201375.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"3118_CR76","first-page":"1205","volume":"26","author":"M Sugano","year":"2011","unstructured":"Sugano M, Shimizu K, Nakano T, et al. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. Oncol Rep. 2011;26(5):1205\u201311.","journal-title":"Oncol Rep"},{"issue":"5","key":"3118_CR77","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cllc.2016.02.001","volume":"17","author":"Y Liu","year":"2016","unstructured":"Liu Y, Kim J, Balagurunathan Y, Li Q, Garcia AL, Stringfield O, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441\u20138.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"3118_CR78","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/bioengineering10070747","volume":"10","author":"B Prencipe","year":"2023","unstructured":"Prencipe B, Delprete C, Garolla E, et al. An explainable radiogenomic framework to predict mutational status of KRAS and EGFR in lung adenocarcinoma patients. Bioengineering. 2023;10(7):747.","journal-title":"Bioengineering"},{"issue":"32","key":"3118_CR79","doi-asserted-by":"publisher","first-page":"52792","DOI":"10.18632\/oncotarget.17782","volume":"8","author":"R Minamimoto","year":"2017","unstructured":"Minamimoto R, Jamali M, Gevaert O, et al. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET\/CT metrics. Oncotarget. 2017;8(32):52792\u2013801.","journal-title":"Oncotarget"},{"key":"3118_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113911","volume":"201","author":"JA Stratmann","year":"2024","unstructured":"Stratmann JA, Althoff FC, Doebel P, Rauh J, Trummer A, H\u00fcnerlit\u00fcrkoglu AN, et al. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany. Eur J Cancer. 2024;201:113911.","journal-title":"Eur J Cancer"},{"issue":"8","key":"3118_CR81","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.21037\/qims-23-1028","volume":"14","author":"X Yao","year":"2024","unstructured":"Yao X, Zhu Y, Huang Z, et al. Fusion of shallow and deep features from 18F-FDG PET\/CT for predicting EGFR-sensitizing mutations in non-small cell lung cancer. Quant Imaging Med Surg. 2024;14(8):5460.","journal-title":"Quant Imaging Med Surg"},{"key":"3118_CR82","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2019.03.025","volume":"132","author":"W Tu","year":"2019","unstructured":"Tu W, Sun G, Fan L, Wang Y, Xia Y, Guan Y, et al. Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer. 2019;132:28\u201335.","journal-title":"Lung Cancer"},{"key":"3118_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24372","author":"JW Ma","year":"2024","unstructured":"Ma JW, Jiang X, Wang YM, et al. Dual-energy CT-based radiomics in predicting EGFR mutation status non-invasively in lung adenocarcinoma. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24372.","journal-title":"Heliyon"},{"issue":"Supplement_5","key":"3118_CR84","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckaa166.1214","volume":"30","author":"H Vila\u00e7a","year":"2020","unstructured":"Vila\u00e7a H. Regulation EU 2017\/745 on medical devices\u2013implementation analysis in Portugal by the distributors. Eur J Public Health. 2020;30(Supplement_5):ckaa166-1214.","journal-title":"Eur J Public Health"},{"key":"3118_CR85","unstructured":"Madiega T. Artificial intelligence act. 2021."},{"issue":"10","key":"3118_CR86","doi-asserted-by":"publisher","DOI":"10.2196\/30545","volume":"23","author":"S Gilbert","year":"2021","unstructured":"Gilbert S, Fenech M, Hirsch M, Upadhyay S, Biasiucci A, Starlinger J. Algorithm change protocols in the regulation of adaptive machine learning\u2013based medical devices. J Med Internet Res. 2021;23(10):e30545.","journal-title":"J Med Internet Res"},{"key":"3118_CR87","unstructured":"US Food and Drug Administration. International medical device regulators forum (IMDRF). US Food and Drug Administration. 2018."},{"key":"3118_CR88","unstructured":"US Food and Drug Administration. Marketing submission recommendations for a predetermined change control plan for artificial intelligence. Machine Learning (AI\/ML)-Enabled Device Software Functions. 2023."},{"issue":"9","key":"3118_CR89","first-page":"2666","volume":"5","author":"C Kludt","year":"2024","unstructured":"Kludt C, Wang Y, Ahmad W, et al. Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms. Cell Rep Med. 2024;5(9):2666\u20133791.","journal-title":"Cell Rep Med"},{"key":"3118_CR90","doi-asserted-by":"crossref","unstructured":"Shariaty F, Pavlov VA, Fedyashina SV, Serebrennikov NA. Integrating deep learning and explainable AI for non-invasive prediction of EGFR and KRAS mutations in NSCLC: a novel radiogenomic approach. In: 2024 V International Conference on Neural Networks and Neurotechnologies (NeuroNT). IEEE; 2024. pp. 32\u201335.","DOI":"10.1109\/NeuroNT62606.2024.10585441"},{"issue":"7","key":"3118_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048008","volume":"11","author":"GS Collins","year":"2021","unstructured":"Collins GS, Dhiman P, Navarro CLA, Ma J, Hooft L, Reitsma JB, et al. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. BMJ Open. 2021;11(7):e048008.","journal-title":"BMJ Open"},{"key":"3118_CR92","doi-asserted-by":"publisher","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","volume":"388","author":"KG Moons","year":"2025","unstructured":"Moons KG, Damen JA, Kaul T, Hooft L, Navarro CA, Dhiman P, et al. PROBAST+ AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505.","journal-title":"BMJ"},{"issue":"5","key":"3118_CR93","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00234-023-03126-9","volume":"65","author":"A Bhandari","year":"2023","unstructured":"Bhandari A, Scott L, Weilbach M, Marwah R, Lasocki A. Assessment of artificial intelligence (AI) reporting methodology in glioma MRI studies using the checklist for AI in medical imaging (CLAIM). Neuroradiology. 2023;65(5):907\u201313.","journal-title":"Neuroradiology"},{"key":"3118_CR94","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-020-1041-y","volume":"26","author":"T Hernandez-Boussard","year":"2020","unstructured":"Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, Shah NH. MINIMAR (minimum information for medical AI reporting): a standards-compliant framework. Nat Med. 2020;26:1320\u20134.","journal-title":"Nat Med"},{"issue":"10","key":"3118_CR95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/iovs.65.10.10","volume":"65","author":"HJ Hogg","year":"2024","unstructured":"Hogg HJ, Martindale AP, Liu X, Denniston AK. Clinical evaluation of artificial intelligence-enabled interventions. Invest Ophthalmol Vis Sci. 2024;65(10):10\u201310.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3118_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04951-6","volume":"22","author":"H Ibrahim","year":"2021","unstructured":"Ibrahim H, Liu X, Rivera SC, Moher D, Chan AW, Sydes MR, et al. Reporting guidelines for clinical trials of artificial intelligence interventions: the SPIRIT-AI and CONSORT-AI guidelines. Trials. 2021;22(1):11.","journal-title":"Trials"},{"issue":"6","key":"3118_CR97","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41591-020-0941-1","volume":"26","author":"V Sounderajah","year":"2020","unstructured":"Sounderajah V, Ashrafian H, Aggarwal R, De Fauw J, Denniston AK, Greaves F, et al. Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: the STARD-AI steering group. Nat Med. 2020;26(6):807\u20138.","journal-title":"Nat Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03118-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:12:07Z","timestamp":1763788327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03118-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":97,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3118"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03118-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"552"}}